Cerebral Amyloid Angiopathy in Patients with Cognitive Impairment: Cerebrospinal Fluid Biomarkers
Dementia and Geriatric Cognitive Disorders · 2024
DOI: 10.1159/000539884 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dementia and Geriatric Cognitive Disorders, 2024. Verfasst von Kasia Gustaw Rothenberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, Amyloid beta-Peptides, Cognitive Dysfunction, Biomarkers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Introduction
Cerebral amyloid angiopathy (CAA) is characterized by amyloid β (Aβ) deposition in brain vessels, leading to hemorrhagic phenomena and cognitive impairment. Magnetic resonance imaging (MRI)-based criteria allow a diagnosis of probable CAA in vivo, but such a diagnosis cannot predict the eventual development of CAA.
Methods
We conducted a retrospective cohort study of 464 patients with cognitive disorders whose data were included in a brain health biobank. De-identified parameters including sex, age, cognitive score, APOE status, and cerebrospinal fluid (CSF) levels of Aβ 1–40, Aβ 1–42, phosphorylated tau, and total tau were assessed in those with and without CAA. Odds ratios (ORs) and 95% confidence intervals (CIs) were determined.
Results
CAA was present in 53 of 464 (11.5%) patients. P-tau level was significantly higher in those with CAA (115 vs. 84.3 pg/mL p = 0.038). In univariate analyses, the risk of developing CAA was higher with increased age (OR, 1.036; 95% CI: 1.008, 1.064; p = 0.011) and decreased CSF level of Aβ 1–40 (OR, 0.685; 95% CI: 0.534, 0.878; p = 0.003). In multivariate analyses, the risk of CAA remained higher with a decreased CSF level of Aβ 1–40 (OR, 0.681; 95% CI: 0.531, 0.874; p = 0.003).
Conclusion
These findings suggest that Aβ 1–40 levels in the CSF might be a useful molecular biomarker of CAA in patients with dementia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Genomic Medicine Institute Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Radiology, Cleveland Clinic, Cleveland, Ohio, USA.
Förderung
- NIA NIH HHS
- NINDS NIH HHS
Zitieren
APA
Rothenberg, K. G., Bekris, L., Leverenz, J. B., Wu, J., Lee, J., Statsevych, V., Ruggieri, P., & Jones, S. E. (2024). Cerebral Amyloid Angiopathy in Patients with Cognitive Impairment: Cerebrospinal Fluid Biomarkers. Dementia and Geriatric Cognitive Disorders. https://doi.org/10.1159/000539884
Vancouver
Rothenberg KG, Bekris L, Leverenz JB, Wu J, Lee J, Statsevych V, et al. Cerebral Amyloid Angiopathy in Patients with Cognitive Impairment: Cerebrospinal Fluid Biomarkers. Dementia and Geriatric Cognitive Disorders. 2024. doi:10.1159/000539884
BibTeX
@article{Rothenberg2024,
author = {Rothenberg, Kasia Gustaw and Bekris, Lynn and Leverenz, James B and Wu, Jenny and Lee, Jonathan and Statsevych, Volodymyr and Ruggieri, Paul and Jones, Stephen E},
title = {Cerebral Amyloid Angiopathy in Patients with Cognitive Impairment: Cerebrospinal Fluid Biomarkers},
journal = {Dementia and Geriatric Cognitive Disorders},
year = {2024},
doi = {10.1159/000539884}
}
EUVIMED